SCHEMBL4965067

SCHEMBL4965067

O=C(NCCc1ccccc1)C1(c2ccc(Cl)cc2)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAAT3 P53816 1/20 0.57
PLAAT5 Q96KN8 1/20 0.57
PLAAT2 Q9NWW9 1/20 0.57
PLAAT4 Q9UL19 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.55
NPC1 O15118 1/20 0.55
CNR1 P21554 1/20 0.55
RAB9A P51151 1/20 0.55
ALDH1A1 P00352 1/20 0.54
CHRM5 P08912 1/20 0.54
CHRM3 P20309 1/20 0.54
MAPT P10636 2/20 0.53
LMNA P02545 1/20 0.53
TAAR1 Q96RJ0 1/20 0.53
HTT P42858 3/20 0.53
KDM4E B2RXH2 1/20 0.53
GAA P10253 1/20 0.53
TP53 P04637 1/20 0.53
MDM2 Q00987 1/20 0.53
EPHX1 P07099 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4969863 0.92 CNR1 (0.56) PLAAT3PLAAT5PLAAT2PLAAT4SMN1; SMN2
SCHEMBL5350234 0.89 SMN1; SMN2 (0.64) PLAAT3PLAAT5PLAAT2PLAAT4SMN1; SMN2
SCHEMBL4961884 0.89 SMN1; SMN2 (0.59) SMN1; SMN2NPC1CNR1RAB9AALDH1A1
SCHEMBL5351676 0.87 HDAC4 (0.61) SMN1; SMN2CNR1ALDH1A1MAPTHTT
SCHEMBL4961877 0.86 KDM4E (0.56) SMN1; SMN2CNR1ALDH1A1MAPTLMNA
SCHEMBL14491537 0.85 PLAAT3 (0.56) PLAAT3PLAAT5PLAAT2PLAAT4SMN1; SMN2
SCHEMBL4966807 0.85 MAPT (0.56) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL989809 0.84 ALDH1A1 (0.77) SMN1; SMN2CNR1ALDH1A1CHRM5CHRM3
SCHEMBL988644 0.83 HDAC4 (0.52) SMN1; SMN2CNR1ALDH1A1CHRM5CHRM3
SCHEMBL4971414 0.83 HTT (0.50) SMN1; SMN2CNR1ALDH1A1CHRM5CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773780-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP claimed
EP-1773780-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-04-18 EP claimed
WO-2006012227-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO claimed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US claimed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288338-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 PLAAT3 668/4885PLAAT5 626/4885PLAAT2 506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.